Cinclus Pharma Holding AB (publ) (J8P)

Overview

Cinclus Pharma Holding AB (publ) operates as a clinical stage pharmaceutical company with a primary focus on the development of innovative drug candidates. Founded in 2014 and headquartered in Stockholm, Sweden, the company has dedicated its efforts towards addressing the needs of patients suffering from gastroduodenal diseases. Through rigorous research and clinical testing, Cinclus Pharma aims to bring new and effective treatments to the market, thereby filling unmet medical needs in gastroenterology.

Products and Services

Linaprazan Glurate:

This lead product from Cinclus Pharma is a novel therapeutic agent designed for the treatment of two significant gastrointestinal conditions - gastroesophageal reflux disease (GERD) and infections caused by the peptic ulcer bacteria Helicobacter pylori (H. pylori). GERD is a chronic condition that affects a substantial portion of the global population, leading to discomfort and a potential risk for more severe esophageal injuries. H. pylori infection is a major cause of peptic ulcers and has been associated with gastric cancer. Linaprazan Glurate's development reflects Cinclus Pharma's commitment to improving the quality of life for individuals affected by these prevalent conditions through innovative pharmaceutical solutions.